Improving experimental drug success rate and accelerating clinical development are top priorities for pharmaceutical and biotech companies.

Improving experimental drug success rate and accelerating clinical development are top priorities for pharmaceutical and biotech companies. Careful decision making is essential to minimize development time, manage costs and improve the probability of commercial success. Modelling and simulation (M&S) can be a very useful strategy to mitigate risks and to make better-informed decisions.

With regards to the drug development process, M&S involves modelling compounds, mechanisms and disease level data based on historical observations and existing real-life data.

Discover the full case study by clicking on the link below.